Doshi Dipal (CIK 1613084) reported 8 SEC Form 4 insider transactions across 2 companies over the past 18 months (most recent 2026-03-03). Recent activity: Buy TRDA (139,400 shares), Sell TRDA (9,869 shares), Sell TRDA (19,181 shares), Buy AZTA (5,663 shares), Sell TRDA (8,723 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-03 | Entrada Therapeutics, Inc. (TRDA) | CEO | Buy | 139,400 | $0 |
| 2026-03-03 | Entrada Therapeutics, Inc. (TRDA) | CEO | Sell | 9,869 | $115,073 |
| 2026-03-03 | Entrada Therapeutics, Inc. (TRDA) | CEO | Sell | 19,181 | $225,569 |
| 2026-02-06 | Azenta, Inc. (AZTA) | Director | Buy | 5,663 | $157,715 |
| 2025-09-04 | Entrada Therapeutics, Inc. (TRDA) | CEO | Sell | 8,723 | $47,366 |
| 2025-03-04 | Entrada Therapeutics, Inc. (TRDA) | CEO | Buy | 116,200 | $0 |
| 2025-03-04 | Entrada Therapeutics, Inc. (TRDA) | CEO | Sell | 17,566 | $205,171 |
| 2025-02-11 | Azenta, Inc. (AZTA) | Director | Buy | 4,040 | $211,373 |
Source: SEC Form 4 filings · as of 2026-03-03